Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $796.57 Average Target Price from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus rating of “Moderate Buy” from the twenty-six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, fifteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $772.7619.

REGN has been the subject of several analyst reports. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective for the company. UBS Group lifted their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dodge & Cox boosted its position in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $628,151,000. AQR Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after buying an additional 606,612 shares during the period. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $343,764,000. Finally, Invesco Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $693.50 on Friday. The firm has a market capitalization of $72.89 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 2.03 and a beta of 0.31. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $598.76 and its 200-day moving average price is $571.04. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.